Quantcast

VitalCare Acquires Diabetes Treatment Center in Scottsdale, Arizona

April 2, 2008

VitalCare Diabetes Treatment Centers, Inc. (PINKSHEETS: VDTI), a Nevada corporation, today announced it has completed the acquisition of the Scottsdale, Arizona diabetes treatment center which has been in operation since 2005. The clinic is currently administering Intracellular Activation Therapy (iCAT) treatments using the FDA approved and US patented technology and proprietary clinical protocols to patients suffering from Type 1, Type 2 and Secondary Complications of Type 2 Diabetes. This announcement is made following an agreement between Joe Thomas, Managing Member of Inpulse Phoenix, a Utah LLC, and VitalCare, for 100% of Inpulse Phoenix, LLC’s interest in the Scottsdale, Arizona diabetes treatment center.

Mr. Jimmy A. McDougald, CEO and Chairman, stated, “This is the first of many acquisitions VitalCare has lined up as part of our acquisition strategy. The Phoenix center is an ideal model with experienced staff and great location as a VitalCare Diabetes Treatment Centers affiliate.”

Melanie Kunz, Clinical Nurse Practitioner and Director of the Scottsdale, Arizona Diabetes Treatment Center, said, “We are excited to be part of the VitalCare quest to bring relief to those suffering from Type 1 and Type 2 diabetes.”

About VitalCare Diabetes Treatment Centers, Inc.

VitalCare Diabetes Treatment Centers, Inc. is a company specializing in providing Administrative, Marketing, Business Development, Strategic Planning, Clinical Oversight and Clinical Management Services to the Diabetes Healthcare Sector, with an emphasis in bringing “Cutting Edge” medical devices and healthcare services direct to consumers, focusing on an emerging FDA approved, US and European Patented technology and treatment intervention for treating Type 1 and Type 2 Diabetes known as “Intracellular Activation Therapy (iCAT).”

Safe Harbor Statement: Forward-looking statements in this release with respect to VitalCare Diabetes Treatment Centers, Inc.’s business, financial condition and results of operations, as well as matters of timing and the prospective terms of the transaction described are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond VitalCare Diabetes Treatment Centers, Inc.’s control with respect to market acceptance of their technology and/or products, whether financing will be available, the effect of the application of acquisition accounting policies as well as certain other risk factors which are and may be detailed from time to time in VitalCare’s filings with the Securities and Exchange Commission.

 For Further Information Contact: VitalCare Diabetes Treatment Centers, Inc. Investor Relations: Office: 1.877.NO-DIABETES Office: 1.909.981.9192 Fax:  1.909.931.1780 Email: info@vitalcaretechnology.com

SOURCE: VitalCare Diabetes Treatment Centers Inc.




comments powered by Disqus